
==== Front
Infect Immun
Infect Immun
iai
Infection and Immunity
0019-9567
1098-5522
American Society for Microbiology 1752 N St., N.W., Washington, DC

39007622
iai00175-24
10.1128/iai.00175-24
iai.00175-24
Minireview
special-series-iai-eciSpecial Section: Minireviews from Early-Career InvestigatorsimmunologyImmunologyEosinophils as drivers of bacterial immunomodulation and persistence
Parrish Katelyn M. 1 Visualization Writing – review and editing *
https://orcid.org/0000-0001-7417-2460
Gestal Monica C. 1 Conceptualization Funding acquisition Investigation Project administration Supervision Validation Visualization Writing – original draft Writing – review and editing mcarges@gmail.com, monica.cartellegestal@lsuhs.edu
*
1 Department of Microbiology and Immunology, Louisiana State University Health Sciences Center at Shreveport , Shreveport, Louisiana, USA
Editor Ottemann Karen M. Department of Microbiology and Environmental Toxicology, University of California at Santa Cruz , Santa Cruz, California, USA

Address correspondence to Monica C. Gestal, mcarges@gmail.com, monica.cartellegestal@lsuhs.edu
The authors declare no conflict of interest.

9 2024
15 7 2024
15 7 2024
92 9 e00175-24Copyright © 2024 Parrish and Gestal.
2024
Parrish and Gestal.
https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

ABSTRACT

Traditionally, eosinophils have been linked to parasitic infections and pathological disease states. However, emerging literature has unveiled a more nuanced and intricate role for these cells, demonstrating their key functions in maintaining mucosal homeostasis. Eosinophils exhibit diverse phenotypes and exert multifaceted effects during infections, ranging from promoting pathogen persistence to triggering allergic reactions. Our investigations primarily focus on Bordetella spp., with particular emphasis on Bordetella bronchiseptica, a natural murine pathogen that induces diseases in mice akin to pertussis in humans. Recent findings from our published work have unveiled a striking interaction between B. bronchiseptica and eosinophils, facilitated by the btrS-mediated mechanism. This interaction serves to enhance pathogen persistence while concurrently delaying adaptive immune responses. Notably, this role of eosinophils is only noted in the absence of a functional btrS signaling pathway, indicating that wild-type B. bronchiseptica, and possibly other Bordetella spp., possess such adeptness in manipulating eosinophils that the true function of these cells remains obscured during infection. In this review, we present the mounting evidence pointing toward eosinophils as targets of bacterial exploitation, facilitating pathogen persistence and fostering chronic infections in diverse mucosal sites, including the lungs, gut, and skin. We underscore the pivotal role of the master regulator of Bordetella pathogenesis, the sigma factor BtrS, in orchestrating eosinophil-dependent immunomodulation within the context of pulmonary infection. These putative convergent strategies of targeting eosinophils offer promising avenues for the development of novel therapeutics targeting respiratory and other mucosal pathogens.

KEYWORDS

whooping cough
pertussis
Bordetella spp.
BtrS
eosinophils
mucosal immunity
immune homeostasis
Th17 microenvironment
long-term protection
persistence
mucosal infections
HHS | NIH | National Institute of General Medical Sciences (NIGMS) P20-GM134974 Gestal Monica C. HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) 5T32HL155022 Parrish Katelyn M. cover-dateSeptember 2024
==== Body
pmcINTRODUCTION

Pathogens have co-evolved with their hosts over centuries, specifically selected for their adeptness in dampening host inflammatory responses, thus facilitating infection establishment and persistence. While extensive research has delved into unraveling the intricate mechanisms by which pathogens evade host immune responses, particularly focusing on classical phagocytes (1–8), neutrophils (9–14), epithelial cells (15–21), and adaptive immune cells (12, 22, 23), the exploration of eosinophils (24, 25) remains in its nascent stages. Traditionally associated with parasitic responses or inflammatory pathologies (26–29), eosinophils have been increasingly implicated in bacterial interactions (30–37). Contemporary research now underscores the pivotal role of these cells during mucosal infections (38, 39), offering a fresh perspective on their functional significance.

In our work, we focus on understanding at the molecular and cellular levels what mechanisms Bordetella spp. utilize to suppress host immune responses to promote initial colonization, persistence, and transmission (23). In our previous work, utilizing the Bordetella bronchiseptica murine model, we discovered a bacterial sigma factor, btrS (40, 41) that is critical to suppress host immune responses and delay adaptive immunity (24, 42). Importantly, in the absence of a functional btrS, eosinophils became essential to promote adaptive immune response (24, 25), pointing toward a possible mechanism by which Bordetella spp. target eosinophils to delay adaptive immune responses.

In this review, we aim to synthesize existing literature linking eosinophils with infections at various mucosal sites, elucidating the diverse functions these cells undertake during different infectious scenarios. Additionally, we will spotlight bacterial effectors known to target eosinophils, either to instigate anti-inflammatory responses or to hyper-activate eosinophils, thereby exacerbating pathology. Finally, leveraging our model system, Bordetella spp., we will provide insights into the potential role of eosinophils in exacerbating pathology and fostering the chronicity of infection.

EOSINOPHIL BIOLOGY AND ROLES IN HUMAN HEALTH

Eosinophil development: the knowns and unknowns

Before discussing our findings, we have to focus on what is known about eosinophils, their biology, and their functions. Eosinophils were initially described by Paul Ehrlich in 1879 due to their affinity for acidophilic dyes (43). Subsequent research by Cline et al. in 1968 delineated key distinctions between eosinophils and neutrophils, encompassing their distribution, quantity, functions, and specific granules (44, 45). Eosinophils, terminal cells once differentiated (46), migrate to tissue and predominantly inhabit mucosal regions, including Peyer’s patches, gastrointestinal (GI) tract, lungs, mammary glands, and the uterus, where they contribute to tissue, metabolic, and immune homeostasis (46, 47).

While circulating, eosinophils are present in relatively small numbers; however, they exhibit rapid recruitment to tissues in response to specific stimuli (48–50). Tissue-resident eosinophils display remarkable adaptability owing to their plasticity (48–51), which is facilitated by membrane receptors that enable them to respond to complement, chemokines, and cytokines (52). Eosinophil receptors include, but are not limited to, pattern-recognition molecules (53) and pathogen-associated molecular patterns via Toll-like receptors (54), such as several TLRs (53), dectin-1 (55), receptor for advanced glycation end products (56), nucleotide-binding oligomerization domains (57), RIG-I-like receptors (57), or C-type lectin receptors (53). While two populations of eosinophils, circulating and tissue resident, have been established for a long time (58), recent technological developments allowed for a rapid increase in our knowledge and understanding of these complex cell populations. RNA transcriptomic analysis has revealed that there are multiple types of eosinophils. First, they were divided into type 1, a more pro-inflammatory and immunomodulatory phenotype, and type 2, with characteristics similar to the eosinophils isolated during asthmatic processes more associated with Th2 and tissue remodeling phenotypes (59). This classification resembles the type 1 and type 2 macrophages (60). Using single-cell RNA sequencing, five distinct subpopulations of eosinophils have been identified: precursor, immature, circulating, basal, and active eosinophils, with the latter being primarily associated with processes within the GI tract (39). Moreover, active eosinophils play a pivotal role in GI mucosal responses, possessing antibacterial and immunoregulatory functions, including responding to interferon-gamma (36, 59) and interleukin-33 (IL-33) (59). However, the exact mechanisms governing the phenotypes and effector functions of these eosinophil subtypes remain largely unexplored.

Eosinophil granules themselves contain an array of molecules, including cationic proteins, cytokines, chemokines, growth factors, and cytotoxic cationic proteins, which are released via degranulation, also in a stimuli-dependent manner (61, 62). However, the specific molecular patterns of eosinophil responses to different stimuli need to be further investigated. Prominent cationic proteins within eosinophil granules include the major basic protein, eosinophil peroxidase (EPX), and the eosinophil-associated RNases eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (63). Secretion of these molecules is mostly associated with degranulation. Eosinophil degranulation can occur via piecemeal degranulation (64), exocytosis, or cytolysis (65). The selection processes that dictate eosinophil-secreted components, as well as the mode in which they are released following activation, remain unclear (65), yet these molecules often serve as biomarkers for several eosinophil-related pathologies (66). This suggests that eosinophil activation and the effector functions that follow are spatiotemporally fine tuned, each containing multiple regulatory steps (38). As a result, such intricate multi-step pathways provide many immunomodulatory targets for pathogens to achieve successful infection, which also may be tissue or pathogen dependent.

It is worth noting that mouse and human eosinophils exhibit some differences, with the most apparent one being that human eosinophils contain Charcot-Leyden crystals (CLC) (67, 68), while murine eosinophils do not (69). Nevertheless, fundamental eosinophil functions, cell morphology, effector mechanisms (e.g., degranulation), and basic biology (46) including eosinopoiesis, which is the production or differentiation into eosinophils, remain largely conserved, allowing for the use of animal models that, although not perfect (70), significantly contribute to studying important aspects of eosinophil functionality and development.

The multifaceted roles of eosinophils

Increased knowledge and understanding of these complex and versatile cells that have been involved in health and disease (26, 43, 71) present an evolutionary enigma (49) about the beneficial or detrimental role eosinophils could possess (43). Eosinophils are notably associated with pathological conditions such as asthma (72), eosinophilic rhinosinusitis (73), eosinophilic esophagitis (74), allergies (28, 71), and fungal infections (75, 76). While the historical focus on eosinophils in infections has predominantly revolved around parasitic (77) and fungal infections (78–82), evidence dating back to the 1970s suggests a direct role of eosinophils in bacterial killing (33, 44, 83, 84). Despite their bactericidal activity appearing seemingly inefficient when compared with neutrophils (33), their ability to successfully phagocytose (45) and kill (44) remains not fully understood. Contrary to the previous perception of eosinophils solely as contributors to disease and helminth infections through proinflammatory responses (85), emerging evidence underscores the complexity of those cells and questions their role during helminth infections as detrimental instead of beneficial, as previously thought (82, 86).

Eosinophils have also been recognized for their roles in lipid metabolism (87–89), vascular homeostasis (90), interactions with the nervous system (91), and cancer immunology (92). Additionally, eosinophils play critical roles in preserving epithelial barrier integrity (93) and releasing cationic proteins that enhance host defense (39, 48). Eosinophils have also been shown to act as regulators of Local Immunity And/or Remodeling/Repair in both health and disease (LIAR hypothesis) (49). Moreover, eosinophils play a critical role in regulatory T cell (Treg) differentiation and tissue homing, mostly via TFG-β (94), altogether highlighting the versatility and multifunctionality of these cells.

To summarize, eosinophil functions could be categorized into four main roles (95). The first includes their terminal effector functions (96), such as phagocytosis (97), eosinophil extracellular trap formation (98, 99), and antibody and complement-mediated cytotoxicity (100). Second, eosinophils participate in tissue repair (28, 63), remodeling (38, 101), and homeostasis by promoting angiogenesis and releasing molecules associated with tissue remodeling (102). The third category is an immune homeostatic role based on their immunomodulatory functions, contributing to immune response polarization (103) of anti-inflammatory or pro-inflammatory responses through early secretion of cytokines and chemokines (104). Finally, the fourth category focuses on the involvement of eosinophils in cell-to-cell communication and signaling, as they share close interactions with epithelial cells via selectins or integrins (43) and they promote immune cell recruitment and activation (105), enhancing antigen presentation (106–110), antigen-specific IgM production (111), and facilitating IgA (112) maintenance through interactions with B cells (48–50).

BORDETELLA SPECIES

The classical Bordetella subspecies, encompassing B. bronchiseptica, Bordetella pertussis, and Bordetella parapertussis, are closely related and well-adapted respiratory pathogens capable of infecting humans and/or animals (113, 114), and the genetic mechanisms that regulate host adaptation are very well conserved among classical Bordetella spp. (115). B. bronchiseptica, infecting a broad host range, is considered the evolutionary predecessor (116–119) to its host-restricted relatives, B. pertussis and B. parapertussis. As such, B. bronchiseptica provides a natural murine infection model that mimics the chronic disease caused by B. pertussis infection in humans (120, 121). Notably, wild-type B. bronchiseptica can persist in the respiratory tract for extended periods, exceeding at times 56 days post-inoculation (24, 25, 42, 122, 123), facilitating the study of disease pathogenesis in a physiologically relevant setting. The low inoculum needed to cause disease, as low as 5 CFU in mice (124), further underscores the effectiveness of the B. bronchiseptica murine model in dissecting the molecular intricacies of the host-pathogen interaction.

Classical Bordetellae exhibit ≥98% nucleotide identity among shared genes (125), as well as nearly identical phosphorylated protein sites throughout their genomes (126) highlighting the level of conservancy of critical functions maintained during the speciation process. The inclusion of several classical Bordetella spp. in our work can provide insights into the functional conservation of genes during the speciation process (127).

ESTABLISHED MECHANISMS OF HOST CELL SIGNALING MANIPULATION DURING BORDETELLA COLONIZATION/INFECTION

Bordetella spp. can successfully adapt to their environment, owing their success to a variety of evolved mechanisms (113, 128). Numerous virulence genes of classical Bordetella are highly conserved at the nucleotide and amino acid levels, regulated by similar two-component systems (TCS) regulatory networks (23). These tightly regulated networks enable the fine-tuned immunosuppression of the host, making Bordetella spp. one of the most successful pathogens identified to date. Over the course of infection, classical Bordetellae employ an array of virulence strategies (129), including the utilization of a multitude of bacterial toxins (130, 131), to evade the activation of immune responses initiated by several cell types throughout the host respiratory tract (132).

The infection starts at the epithelium, the first barrier encountered by the bacteria. Initial attachment is mediated by interactions between filamentous hemagglutinin (FHA) (133) and lipid rafts at the host cell membrane (134). Fimbriae (135), pertactin (136), and pertussis toxin (PTX) (137) also contribute to adherence, though to a lesser extent (134, 138). Following attachment to the epithelium, Bordetella spp. utilize the adenylate cyclase toxin-hemolysin (ACT) to bind the CD11b/CD18 receptor (139) of target host cells. Both ACT and FHA have been shown to potentiate attachment to the alveolar epithelium (140). During B. pertussis internalization by epithelial cells, Bordetella spp. impede phagosome acidification to survive intracellularly (19) to escape host immune recognition. To cross the epithelial barrier, ACT causes the disruption of tight junctions, while in parallel causing enhancement of mucus production (141), and elevates IL-6 secretion (142). The T3SS also contributes to colonization of the respiratory tract (127, 143), possibly associated with rapid induction of cytotoxicity to epithelial cells. However, it is important to note that uncontrolled epithelial necrosis in vivo has not been observed at similar levels that have been observed in vitro (143).

Following translocation across the epithelial barrier, innate immune cells contribute to host defense and become targets of classical Bordetellae to promote the establishment of the infection. Bordetella spp. have been shown to induce macrophage cytotoxicity and dampen overall immune signaling cascades (42). PTX binds to the macrophage’s membrane via integrin CR3 (144), and following initial attachment, PTX has similar functions as those performed during epithelial cell infection (145), including inflammasome activation, skewing the phenotype from M1 to M2 (2, 146, 147), or interfering with phagosome maturation (144). While PTX induces macrophage cytotoxicity (7), it has been shown that purified PTX inhibited apoptosis of bone marrow-derived macrophages (145, 148). ACT can induce apoptosis in both macrophages (149) and neutrophils (6, 150), mediated by calcium ion influx (151). But recently, it has been shown that ACT can also inhibit monocyte-to-macrophage differentiation, likely promoting survival of Bordetella spp. within the host (152), further highlighting the versatility and complexity of some of these virulence factors.

PTX as well as other virulence factors also promote delayed recruitment of neutrophils (12, 153, 154). Similarly to macrophages, ACT promotes cell death in neutrophils (155), while FHA can promote inhibition of phagocytosis, enhancement of apoptosis, and induction of formation of neutrophil extracellular traps (156). T3SS inhibits neutrophil phagocyte functions in vitro (157), recruitment of inflammatory innate cells to the site of infection (158), and induction of innate and adaptive immune responses in vivo (159), suggesting a strong association between a functional T3SS and increased persistence of Bordetella spp. infection (123, 160).

Overall, Bordetella spp. utilize a multitude of context-dependent strategies to manipulate host immune cell signaling pathways, which contribute to initial colonization and establishment of infection. But importantly, how the different functions performed by one toxin are regulated in a cell-specific manner remains unknown.

The BtrS immunosuppressive pathway: a tool to investigate key host immune players

These toxins aforementioned are not constitutively expressed, and as any other well-adapted organism, Bordetella spp. also need to harbor mechanisms to finely tune the expression of genes that are required to adapt to specific host compartments. Since the early investigations that examined Bordetella spp. regulatory virulence mechanisms pioneered by established scientists such as Rappuoli et al. (161–163) and Falkow et al. (162, 164–170), many of their successors (171–175) continue to unravel the intricacies behind the great success of this highly transmissible pathogen that continue to rise despite the vaccine being widely distributed for nearly a century. Three regulatory TCS have been extensively investigated (23): BvgAS (170, 172, 176), RisAS (177, 178), and PlrSR (179, 180), yet only some of the genes regulated by these systems have been characterized. In addition to these regulatory TCS, chaperones (181–183), ci-d-GMP (184), sRNAs (172, 185), and sigma factors (23) are only a few additional regulators that finely tune bacterial gene expression to optimize its performance in every environment, including host immune suppression to promote colonization (186), persistence (42), and transmission (187). One gene that is regulated by BvgAS is the extra-cytoplasmic sigma factor btrS (40) [also referred to as brpL (188)], which was identified (40) and defined (41) as one of the main regulators of the T3SS by Jeffery F. Miller’s group and is the central focus of our laboratory.

Our work explored the role of btrS using a murine infection model of B. bronchiseptica, revealing that btrS regulates many known and unknown virulence factors beyond the T3SS (42). In the absence of btrS, murine B. bronchiseptica infection clears more rapidly from the respiratory tract due to a stronger and more effective immune response (42) (Fig. 1). The immunity generated by the btrS-null mutant results in long-lasting sterilizing immunity in the murine model that lasts up to 15 months in the lungs and 7 months in the nasal cavity (189). Importantly, our results indicate that early adaptive immune responses generated by infection with the btrS-null strain required eosinophils (25). Combining RB50, a wild-type bacterium that is highly successful at suppressing host immune responses, and RB50ΔbtrS, which is rapidly clear and generates a profound immune response overpassing convalesce immunity (189), provides a unique opportunity to better understand the molecular mechanisms that underlie pathogenic success, which we interpret as increasing persistence and enhancing transmission. Our data point toward eosinophils as drivers of efficient adaptive protective immune responses after btrS-null infection (24, 25); however, this role for eosinophils is not noted during infection with the RB50 strain or any other Bordetella spp. or many respiratory bacteria, suggesting that Bordetella spp., and possibly other respiratory pathogens, are so well adapted to suppress eosinophil effector function that the role of these cells is masked.

Fig 1 Predicted kinetics of the immune responses to RB50 and RB50ΔbtrS. The dotted lines indicate lung bacterial burden (blue shows RB50 and red shows RB50ΔbtrS). Immune cell recruitment to the lungs is shown in green (neutrophils), magenta (macrophages), black (eosinophils), yellow (T cells), and lilac (B cells). Relative numbers are indicated in the Y-axis, while days post-infection are shown in the X-axis.

EOSINOPHILS AS BACTERIAL TARGETS TO FACILITATE BORDETELLA PERSISTENCE

Utilizing the btrS-null mutant revealed a role for eosinophils previously unnoted. Although some Bordetella spp. have been indirectly associated with eosinophils in many studies over the years, this is a logical observation, as epithelial cells and eosinophils exhibit intimate crosstalk and elaborate signaling networks (102). As early as 1969, the utilization of a B. pertussis-treated murine model was reported for assessing eosinophil cell responses to antigenic challenges (190), although no effects on eosinophils was observed, this primed the field and other studies of hypersensitivity in Bordetella followed (190–192). Bordetella spp. infections have also been recognized as stimuli for triggering asthmatic and allergic events (192). To further intertwine Bordetella and eosinophils, both acellular and live-attenuated pertussis vaccines have been associated with preventing asthma exacerbations (193–198).

One of the drivers of asthmatic airway remodeling is sphingosine-1 phosphate (S1P) (199). During B. pertussis infections, in vivo inhibition of sphingosine-1 phosphate (S1P) signaling in murine models reduces Bordetella pathology without affecting bacterial burden (200). S1P activation promotes airway remodeling, recruitment of eosinophils expressing S1P receptors, and induction of other Th2-related cells (61) and increases smooth muscle mass (201) during asthmatic processes. This is coupled with epithelial-mesenchymal transition, which contributes to elevated lung resistance and fibroblast activation and results in hyperresponsiveness (202), potentially establishing a mechanistic link between Bordetella infections and the asthma-like pathologies, symptoms, and long-lasting consequences that are present during and after pathogen clearance.

Similarly, low concentrations of vasoactive intestinal peptide or VIP mediate asthma pathology (203) following interaction with one of its receptors, VPAC2. Investigating if the VIP/VPAC2 axis can interfere with Bordetella spp. infectious process, our result revealed that the three classical Bordetella spp. utilize the T3SS to stimulate VPAC2 signaling and promote persistence in the lower respiratory tract (123). In the absence of functional VPAC2 signaling, Bordetella spp. are cleared more rapidly. Furthermore, our results indicate that Bordetella spp. utilize the T3SS to activate VPAC2 signaling, leading to increased persistence, especially in the lower respiratory tract.

Indirect evidence for a potential role of Th2 inflammation in Bordetella spp. infections has been shown using a rabbit model of Bordetella bronchiseptica co-infection with helminths. Helminths are known to activate eosinophils and induce Th2 responses. During rabbit co-infection of B. bronchiseptica and helminths, the results showed enhanced shedding and transmission of Bordetella (204). Although this evidence is correlative, it points to a relationship between Bordetella spp. and eosinophils where we envision Bordetella spp. suppress eosinophil pro-inflammatory functions and stimulate tissue remodeling associated with the classical bronchoconstriction observed in pertussis patients (205).

Taking advantage of our in vivo murine infection model encompassing wild-type B. bronchiseptica (RB50) and a mutant strain lacking btrS (RB50∆btrS) (25), we investigated the contribution of eosinophils to the generation of adaptive immune responses during infections with the btrS-null strain. Our results revealed that in the absence of btrS, lung eosinophils promote recruitment of B/T cells to the site of infection, with T helper (Th) lymphocytes skewed toward Th1/17 phenotypes and increased production of IgA from B cells. Furthermore, this immune response was mediated by eosinophil-derived chemokine (C-motif) ligand 1 (XCL1) (24). Together, these recruited cells formed an inducible bronchus-associated lymphoid tissue (iBALT) with eosinophils within or proximal to these aggregates. In the absence of eosinophils, B/T cell recruitment, IgA production, and iBALT formation were suppressed, suggesting a role for eosinophils as mediators of protective adaptive immune responses (24) (Fig. 2).

Fig 2 Multifaced roles of eosinophils. Eosinophils can be considered into two categories, more anti-inflammatory phenotype (blue) associated with bacterial persistence or more pro-inflammatory (red) where eosinophils actively contribute to bacterial killing during infection.

This discovery may be the first step in elucidating the hitherto unrecognized effector functions of eosinophils in response to other respiratory pathogens. However, this discovery was made using our btrS-deficient B. bronchiseptica strain; the role of eosinophils during wild-type infection is drastically different, with no effect for eosinophils noted at all, suggesting that B. bronchiseptica is so well adapted to suppress eosinophil activity and that the presence or absence of eosinophils has no apparent effect on bacterial persistence.

Overall, the evidence provided in this section underscores a sound connection between the immunomodulatory roles of Bordetella spp. and eosinophils, posing the bigger question of whether these immune cells are direct bacterial targets or somehow instigators of bacterial infections. These observations collectively highlight the intricate interplay between Bordetella spp. and eosinophils, shedding light on potential therapeutic approaches. Our proposed model postulates that Bordetella spp. infections initiate asthmatic-like processes, and with a higher frequency of infections, the inflammation becomes chronic (206, 207), exacerbating associated symptoms and promoting anti-inflammatory microenvironments that allow for bacterial persistence. These strategies might also be conserved among other respiratory pathogens, as similar connections have been identified, revealing the hidden role of these cells as mediators of immune responses.

BACTERIAL EXPLOITATION OF EOSINOPHILS BEYOND BORDETELLA

Eosinophils in GI: Helicobacter pylori infection

Many of the functions and roles eosinophils play during mucosal infections have long been intriguing. In the GI tract, research suggests a critical role for eosinophils during Helicobacter pylori infections (208) and the involvement of these cells to facilitate persistence (209). H. pylori outer membrane vesicles promote eosinophil degranulation, and the vacuolating cytotoxin VacA enhances the secretion of EPC. Moreover, this effect is also mediated by epithelial cells, highlighting the crosstalk between epithelial cells and eosinophils during GI infections (210). It has been shown that the H. pylori-derived peptide, HP(2-20), induces eosinophil recruitment to the superficial layer of the mucosa, leading to eosinophil activation. This facilitates wound healing via eosinophil-derived vascular endothelial growth factor A and tumor growth factor beta, which promote tissue remodeling and integrity (32, 211, 212). Eosinophils also modulate T cell responses during H. pylori infection utilizing the type 4 secretion system to promote the secretion of the anti-inflammatory molecule, program death ligand 1, which dampens immune responses (37). The fine-tuned relationship between H. pylori and eosinophils is becoming more complex as we better understand the cross-signaling between H. pylori and eosinophils. H. pylori harbor chemoreceptors, one being encoded by the tlpA gene. tlpA senses beneficial molecules such as arginine, fumarate, and cysteine, which lead to increased growth showed through an in vivo infection model. Johnson et al. recently showed that tlpA suppresses eosinophil recruitment at later times post-infection which might correlate with the increased persistence observed during infection with the wild-type H. pylori (213), as previous evidence has shown that eosinophil depletion enhances the clearance of H. pylori infection, amplifying Th1 responses (37–39). Moreover, during H. pylori infection, deregulation of a proliferation-inducing ligand (APRIL) has been associated with tumorigenesis, and the population of APRIL-producing eosinophils infiltrated tumors in higher numbers in patients with H. pylori infection, suggesting a pro-tumorigenesis role for eosinophils in H. pylori-infected patients (214).

Tissue-resident eosinophils also play a critical role in maintaining tissue homeostasis (47), communicating closely with the gut microbiota (215), potentially impacting the number of neonatal infection cases of H. pylori (38). Furthermore, correlative evidence has suggested that H. pylori infection protects against eosinophilic esophagitis (216, 217) and reduced responses to allergic asthma (218, 219), contributing to a protective role of neonatal H. pylori infection in mitigating the severity of asthma and allergic airway inflammation, possibly via Treg-mediated mechanisms (218). However, it is crucial to note that H. pylori infections can also trigger autoimmunity, a phenomenon requiring further investigation (Fig. 2).

Eosinophils in GI: Citrobacter rodentium infection

There are other bacterial GI pathogens that also show close interplay with eosinophils. Recent findings indicate that eosinophil-deficient mice show increased susceptibility to Citrobacter rodentium infection, accompanied by heightened Th17 responses and exacerbated disease pathology (39). Similarly, selective deletion of ATG5 in the eosinophil lineage resulted in impaired eosinophil effector function, resulting in faster clearance of C. rodentium infection (220). Eosinophils effectively kill C. rodentium both in vitro and in vivo through eosinophilic cationic proteins associated with extracellular traps (37) and can present antigens via MHC-I39, underscoring their critical roles during bacterial infections in the GI tract.

Eosinophils in the skin: Staphylococcus aureus

Atopic dermatitis is one of the most common eosinophilic disorders generally associated with recurrent Staphylococcus aureus skin infections (221); eosinophils have also been shown to be involved in immune responses and allergic reactions to S. aureus (96). When exposed to S. aureus, eosinophils produce superoxides, release granule-derived molecules (e.g., ECP), and exhibit bactericidal activity for infection clearance (222). The S. aureus peptidoglycan has been identified to activate eosinophil recruitment (223). There is additional evidence of eosinophils being a direct target for promoting an anti-inflammatory environment during S. aureus infection in vivo (224) (Fig. 2).

Eosinophils in the lung

We have discussed the role of eosinophils during Bordetella spp. infections (24), but this is not the only lung pathogen that has been associated with eosinophils. Mycobacterium tuberculosis (Mtb) has also been closely associated with eosinophils (225), and persistent eosinophilia in patients with tuberculosis has been commonly reported (225, 226). Eosinophils are a critical component of the immune response to generate protection against Mtb infection (227). It has been shown that decreased numbers of peripheral eosinophils correlate with disease severity caused by Mtb infection. Moreover, eosinophils are present on the rim area of granulomas which actively secrete EPX and diffuse to the central necrotic core area found in pulmonary lesions. Eosinophils do not appear to internalize Mtb, but rather, these cells degranulate and secrete EPX, which serves to aid in controlling bacterial growth. Importantly, these findings were obtained in separate animal and Mycobacterium spp. models, indicating a high level of conservation in this type of immune response (228). Further highlighting the important role eosinophils play during Mtb infection, they are one of the first cells to be recruited to the infection site and rapidly interact with tissue-resident macrophages. Tissue-resident macrophages can contain Mtb, and Mtb-infected cells upregulate the oxysterol-producing enzyme Ch25h, facilitating binding to the oxysterol receptor GPR183 expressed on circulating eosinophils and triggering migration to the lungs during early stages of pulmonary Mtb infection (229). In conclusion, eosinophils play a crucial role in the immune response to M. tuberculosis infections, with evidence suggesting their involvement in controlling bacterial growth within pulmonary lesions. Their early recruitment to the site of infection and interaction with infected cells highlight their importance in orchestrating protective mechanisms against Mtb, underscoring the significance of understanding their function in tuberculosis pathogenesis and potential therapeutic interventions (Fig. 2).

PERSPECTIVES

For long, eosinophils have been considered the primary responders to parasitic infections as well as the main responsible cells for asthmatic and allergic reactions. However, cumulative evidence has been pointing toward a more elegant and subtle role for these cells in the coordination of immune responses to other stimuli and pathogens. Cumulative evidence indicates eosinophils contribute to viral (109, 230–232) and fungal (233–235) infections, although we have not focused on these aspects during this review. In the context of bacterial infection, it has been shown that bacteria utilize specific toxins or secreted effectors to establish infection in the epithelia, cross the epithelial barrier, and manipulate phagocytes and neutrophils to redirect the fate of host immune responses toward mechanisms that will facilitate establishment of infection and persistence. However, despite our deep knowledge of some bacterial mechanisms, the discovery of the btrS-immunosuppressive pathway has revealed that our knowledge represents only the tip of the iceberg when discussing bacterial immunomodulation of hosts.

One of the main dogmas challenged with the btrS-null mutant requires the revision of the convalesce immunity as a gold standard. Our previous work revealed that in the absence of btrS, not only recruitment of adaptive immune cells is accelerated leading to more rapid clearance of infection (42). Furthermore, we have observed that the immunity provided by prior challenge with btrS-null is more robust and long lasting than that provided by prior infection (189). But why to be surprised if it is well accepted that bacteria suppress host immune response? Then, it would make sense that infection with a mutant that cannot suppress, manipulate, or evade immune responses will result in better immunity.

Another innovative result focuses on the evidence that eosinophils are required for adaptive immune responses to infection with the btrS-null mutant. These results encompass multiple concepts; on one side, this suggests that eosinophils might be required for protective immune responses and that in fact, these cells contribute to the robust B and T cell responses observed after btrS-null infection. Secondly, the fact that a function for eosinophils has not been previously noted might suggest that well-adapted pathogens have been selected for their ability to suppress eosinophil effector functions to promote their survival and persistence within the host. This will be supported by our findings with the btrS-null mutant (24) as well as the previously published evidence on other models such as the H. pylori infection model (38). Could it be that pathogens that cause chronic pathologies share a convergent core strategy of targeting eosinophils to promote persistence? What role could eosinophils serve for obligate intracellular bacterial pathogens? Could it be possible that allergies and asthma are the result of pathogens manipulating eosinophils during infections leading to hyper-reactivity of these cells? In fact, the evidence herein presented shows how at different mucosal sites a myriad of pathogens use convergent strategies to target these cells and promote degranulation to initiate inflammation leading to allergic states of disease or inducing secretion of anti-inflammatory signaling cascades that enhance pathogen persistence leading to chronic infections.

How eosinophils interact with mucosal pathogens is an open frontier of discovery that has decades of work to be done by many fields of researchers. Using current knowledge about how Bordetella spp. modulate host immune cells and barriers spanning over the whole infection life cycle, as well as illuminating current understandings of the role of eosinophils during infection, our future work aims to identify a central role for eosinophils during this process. We envision that Bordetella spp. harbor specific virulence mechanisms or factors that target eosinophils to promote persistence as well as pathology during the infectious process. Furthermore, we expect these strategies will be conserved among different Bordetella spp. Here, we propose that these once underappreciated eosinophils are not only an integral but also common target for establishing persistence and they may serve as the missing link to other enigmatic pathogens that have evolved similar modes of action to those of classical Bordetellae (Fig. 3).

Fig 3 Predicted role of eosinophils during Bordetella spp. infections. Bordetella spp. secrete “Bordetella eosinophil factors” that will suppress eosinophil effector function leading to persistence. Deletion of the bacterial sigma factor btrS results in no suppression of eosinophils. In this context, eosinophils promote adaptive immune responses, formation of germinal centers in the lungs, and rapid clearance of infection.

By unraveling the complexities of eosinophil-pathogen interactions, we can pave the way for innovative therapeutic interventions targeting these immune cells and enhance our ability to combat bacterial infections effectively. Altogether, appreciation of these findings only highlights the need for a better understanding of how eosinophils function during bacterial infections and how these mechanisms can be targeted for therapeutic and preventative measures against infection, transmission, and also disease severity induced by these pathogens. Using our Bordetella bronchiseptica and Bordetella pertussis murine models, our work will focus on unravelling the cellular and molecular mechanisms by which Bordetella target eosinophils during infection as well as the role of eosinophils during Bordetella infections. This twofold approach will provide a novel view for eosinophils during the infectious process, and we expect that our results would provide a better understanding on the inter-signaling between Bordetella and eosinophils during infection.

ACKNOWLEDGMENTS

We would like to acknowledge the support of the funding bodies, which had no role in the study design, data collection, data analysis, or data interpretation. We would like to acknowledge the NIH-NIGMS COBRE award P20-GM134974-0181, Center for Applied Immunology and Pathological Processes at LSU Health Sciences Center at Shreveport. We would like to acknowledge and thank the support from the NIH Predoctoral Multidisciplinary Training in Cardiovascular Pathophysiology (MTCP) Fellowship (5T32HL155022-03) provided by the Center for Cardiovascular Diseases and Sciences (CCDS) at LSU Health Sciences Center at Shreveport; Intramural Research Council Seed Package support from LSU Health Sciences Center Shreveport; and start-up package from LSU Health Sciences Center Shreveport.

We would like to apologize to those researchers that have made great contributions in this field that have not been included in this manuscript due to space constraints.

We want to also acknowledge several of our collaborators and friends that have kindly nominated our laboratory to be part of this IAI special series of Minireviews from Early-Career Investigators. We would also like to acknowledge Dr. Alison Criss, who provided comments and suggestions that improved the manuscript. We would also like to acknowledge Dr. Jonathan Kagan and Dr. Matthew Lawrenz for the great brainstorming discussions that served as insipiration for some of the sections of the manuscript.

Katelyn M. Parrish is currently a PhD student in the department of Microbiology & Immunology at LSU Health Sciences Center at Shreveport, Louisiana, USA. She is in Dr. Monica Gestal’s lab, and her thesis work focuses on the molecular immunosuppressive mechanisms utilized by Bordetella spp. infection in order to promote persistence, with an emphasis on the modes by which eosinophils are modulated during infection. She received her Bachelor of Science degree in biological sciences from Southeastern Louisiana University as a first-generation graduate, with a concentration in molecular biology/microbiology and a minor in chemistry.

Monica C. Gestal, PhD, serves as an Assistant Professor in Microbiology and Immunology at the Louisiana State University Health Science Center in Shreveport. She obtained her BA and PhD degrees from the University of A Coruña and pursued postdoctoral research at the University of Nottingham. She obtained a Principal Investigator position in Ecuador. However, desiring a shift in her research direction, she returned to a postdoctoral position at the University of Georgia. Dr. Gestal investigates the cellular and molecular mechanisms that Bordetella spp. employ to overcome host immune responses, focusing on the role of eosinophils as drivers of adaptive immune responses and the molecular mechanisms Bordetella spp. utilize to suppress eosinophil effector functions. Beyond her scientific pursuits, Dr. Gestal is committed to fostering diversity, equity, and inclusion, which is reflected in her active involvement in service activities within Shreveport, Louisiana. As a member of the American Society for Microbiology Council on Microbial Sciences since 2021, she has taken part on several HMB activities, including the retreat, where she was part of the organizing committee. Dr. Gestal is now the Host Microbe Biology (HMB) Community Lead since 2023.
==== Refs
REFERENCES

1 Ahmad JN, Sebo P. 2020. Adenylate cyclase toxin tinkering with monocyte-macrophage differentiation. Front Immunol 11 :2181. doi:10.3389/fimmu.2020.02181 33013916
2 Petráčková D, Farman MR, Amman F, Linhartová I, Dienstbier A, Kumar D, Držmíšek J, Hofacker I, Rodriguez ME, Večerek B. 2020. Transcriptional profiling of human macrophages during infection with Bordetella pertussis. RNA Biol 17 :731–742. doi:10.1080/15476286.2020.1727694 32070192
3 Valdez HA, Oviedo JM, Gorgojo JP, Lamberti Y, Rodriguez ME. 2016. Bordetella pertussis modulates human macrophage defense gene expression. Pathog Dis 74 :ftw073. doi:10.1093/femspd/ftw073 27465637
4 Hewlett EL, Donato GM, Gray MC. 2006. Macrophage cytotoxicity produced by adenylate cyclase toxin from Bordetella pertussis: more than just making cyclic AMP! Mol Microbiol 59 :447–459. doi:10.1111/j.1365-2958.2005.04958.x 16390441
5 Siciliano NA, Skinner JA, Yuk MH. 2006. Bordetella bronchiseptica modulates macrophage phenotype leading to the inhibition of CD4+ T cell proliferation and the initiation of a Th17 immune response. J Immunol 177 :7131–7138. doi:10.4049/jimmunol.177.10.7131 17082630
6 Gueirard P, Druilhe A, Pretolani M, Guiso N. 1998. Role of adenylate cyclase-hemolysin in alveolar macrophage apoptosis during Bordetella pertussis infection in vivo. Infect Immun 66 :1718–1725. doi:10.1128/IAI.66.4.1718-1725.1998 9529102
7 Khelef N, Guiso N. 1995. Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolysin. FEMS Microbiol Lett 134 :27–32. doi:10.1111/j.1574-6968.1995.tb07909.x 8593951
8 Bromberg K, Tannis G, Steiner P. 1991. Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect Immun 59 :4715–4719. doi:10.1128/iai.59.12.4715-4719.1991 1937833
9 Corey SJ, Rosoff PM. 1989. Granulocyte-macrophage colony-stimulating factor primes neutrophils by activating a pertussis toxin-sensitive G protein not associated with phosphatidylinositol turnover. J Biol Chem 264 :14165–14171.2547784
10 Weingart CL, Broitman-Maduro G, Dean G, Newman S, Peppler M, Weiss AA. 1999. Fluorescent labels influence phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 67 :4264–4267. doi:10.1128/IAI.67.8.4264-4267.1999 10417202
11 Harvill ET, Cotter PA, Yuk MH, Miller JF. 1999. Probing the function of Bordetella bronchiseptica adenylate cyclase toxin by manipulating host immunity. Infect Immun 67 :1493–1500. doi:10.1128/IAI.67.3.1493-1500.1999 10024599
12 Kirimanjeswara GS, Agosto LM, Kennett MJ, Bjornstad ON, Harvill ET. 2005. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest 115 :3594–3601. doi:10.1172/JCI24609 16294220
13 Storisteanu DML, Pocock JM, Cowburn AS, Juss JK, Nadesalingam A, Nizet V, Chilvers ER. 2017. Evasion of neutrophil extracellular traps by respiratory pathogens. Am J Respir Cell Mol Biol 56 :423–431. doi:10.1165/rcmb.2016-0193PS 27854516
14 Gorgojo J, Scharrig E, Gómez RM, Harvill ET, Rodríguez ME. 2017. Bordetella parapertussis circumvents neutrophil extracellular bactericidal mechanisms. PLoS One 12 :e0169936. doi:10.1371/journal.pone.0169936 28095485
15 Fullen AR, Gutierrez-Ferman JL, Rayner RE, Kim SH, Chen P, Dubey P, Wozniak DJ, Peeples ME, Cormet-Boyaka E, Deora R. 2023. Architecture and matrix assembly determinants of Bordetella pertussis biofilms on primary human airway epithelium. PLoS Pathog 19 :e1011193. doi:10.1371/journal.ppat.1011193 36821596
16 Kroes MM, Miranda-Bedate A, Jacobi RHJ, van Woudenbergh E, den Hartog G, van Putten JPM, de Wit J, Pinelli E. 2022. Bordetella pertussis-infected innate immune cells drive the anti-pertussis response of human airway epithelium. Sci Rep 12 :3622. doi:10.1038/s41598-022-07603-8 35256671
17 Bianchi M, Sivarajan R, Walles T, Hackenberg S, Steinke M. 2021. Susceptibility of primary human airway epithelial cells to Bordetella pertussis adenylate cyclase toxin in two- and three-dimensional culture conditions. Innate Immun 27 :89–98. doi:10.1177/1753425920979354 33317363
18 Malandra A, Rahman WU, Klimova N, Streparola G, Holubova J, Osickova A, Bariselli S, Sebo P, Osicka R. 2021. Adenylate cyclase toxin elicits airway mucin secretion through activation of the cAMP response element binding protein. Int J Mol Sci 22 :9064. doi:10.3390/ijms22169064 34445770
19 Lamberti Y, Gorgojo J, Massillo C, Rodriguez ME. 2013. Bordetella pertussis entry into respiratory epithelial cells and intracellular survival. Pathog Dis 69 :194–204. doi:10.1111/2049-632X.12072 23893966
20 Ishibashi Y, Nishikawa A. 2002. Bordetella pertussis infection of human respiratory epithelial cells up-regulates intercellular adhesion molecule-1 expression: role of filamentous hemagglutinin and pertussis toxin. Microb Pathog 33 :115–125. doi:10.1006/mpat.2002.0517 12220988
21 Ishibashi Y, Relman DA, Nishikawa A. 2001. Invasion of human respiratory epithelial cells by Bordetella pertussis: possible role for a filamentous hemagglutinin Arg-Gly-Asp sequence and α5β1 integrin. Microb Pathog 30 :279–288. doi:10.1006/mpat.2001.0432 11373122
22 Klimova N, Holubova J, Streparola G, Tomala J, Brazdilova L, Stanek O, Bumba L, Sebo P. 2022. Pertussis toxin suppresses dendritic cell-mediated delivery of B. pertussis into lung-draining lymph nodes. PLoS Pathog 18 :e1010577. doi:10.1371/journal.ppat.1010577 35666769
23 Gestal M.C, Whitesides LT, Harvill ET. 2019. Integrated signaling pathways mediate Bordetella immunomodulation, persistence, and transmission. Trends Microbiol 27 :118–130. doi:10.1016/j.tim.2018.09.010 30661570
24 First NJ, Parrish KM, Martínez-Pérez A, González-Fernández Á, Bharrhan S, Woolard M, McLachlan JB, Scott RS, Wang J, Gestal MC. 2023. Bordetella spp. block eosinophil recruitment to suppress the generation of early mucosal protection. Cell Rep 42 :113294. doi:10.1016/j.celrep.2023.113294 37883230
25 Gestal MC, Blas-Machado U, Johnson HM, Rubin LN, Dewan KK, Bryant C, Tiemeyer M, Harvill ET. 2020. Disrupting Bordetella immunosuppression reveals a role for eosinophils in coordinating the adaptive immune response in the respiratory tract. Microorganisms 8 :1808. doi:10.3390/microorganisms8111808 33212993
26 Syeda MZ, Hong T, Zhang C, Ying S, Shen H. 2023. Eosinophils: a friend or foe in human health and diseases. Kidney Dis (Basel) 9 :26–38. doi:10.1159/000528156 36756082
27 Jackson DJ, Akuthota P, Roufosse F. 2022. Eosinophils and eosinophilic immune dysfunction in health and disease. Eur Respir Rev 31 :210150. doi:10.1183/16000617.0150-2021 35082127
28 Lombardi C, Berti A, Cottini M. 2022. The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol 3 :42–53. doi:10.1016/j.crimmu.2022.03.002 35496822
29 Rosenberg HF, Druey KM. 2018. Modeling asthma: pitfalls, promises, and the road ahead. J Leukoc Biol 104 :41–48. doi:10.1002/JLB.3MR1117-436R 29451705
30 Gevaert E, Zhang N, Krysko O, Lan F, Holtappels G, De Ruyck N, Nauwynck H, Yousefi S, Simon H-U, Bachert C. 2017. Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation. J Allergy Clin Immunol 139 :1849–1860. doi:10.1016/j.jaci.2017.01.019 28216437
31 Hosoki K, Nakamura A, Kainuma K, Sugimoto M, Nagao M, Hiraguchi Y, Tanida H, Tokuda R, Wada H, Nobori T, Suga S, Fujisawa T. 2013. Differential activation of eosinophils by bacteria associated with asthma. Int Arch Allergy Immunol 161 Suppl 2 :16–22. doi:10.1159/000350338 23711849
32 Prevete N, Rossi FW, Rivellese F, Lamacchia D, Pelosi C, Lobasso A, Necchi V, Solcia E, Fiocca R, Ceppa P, Staibano S, Mascolo M, D’Argenio G, Romano M, Ricci V, Marone G, De Paulis A. 2013. Helicobacter pylori HP(2-20) induces eosinophil activation and accumulation in superficial gastric mucosa and stimulates VEGF-α and TGF-β release by interacting with formyl-peptide receptors. Int J Immunopathol Pharmacol 26 :647–662. doi:10.1177/039463201302600308 24067461
33 DeChatelet LR, Migler RA, Shirley PS, Muss HB, Szejda P, Bass DA. 1978. Comparison of intracellular bactericidal activities of human neutrophils and eosinophils. Blood 52 :609–617. doi:10.1182/blood.V52.3.609.609 678676
34 Leyva Covian F. 1977. [Eosinophils. III. Phagocytosis]. Rev Clin Esp 144 :167–171.320634
35 Cohen SG, Sapp TM. 1969. Phagocytosis of bacteria by eosinophils in infectious-related asthma. J Allergy 44 :113–117. doi:10.1016/0021-8707(69)90007-0 4979319
36 Gurtner A, Gonzalez-Perez I, Arnold IC. 2021. Intestinal eosinophils, homeostasis and response to bacterial intrusion. Semin Immunopathol 43 :295–306. doi:10.1007/s00281-021-00856-x 33929602
37 Arnold IC, Artola-Borán M, Tallón de Lara P, Kyburz A, Taube C, Ottemann K, van den Broek M, Yousefi S, Simon H-U, Müller A. 2018. Eosinophils suppress Th1 responses and restrict bacterially induced gastrointestinal inflammation. J Exp Med 215 :2055–2072. doi:10.1084/jem.20172049 29970473
38 Gurtner A, Crepaz D, Arnold IC. 2023. Emerging functions of tissue-resident eosinophils. J Exp Med 220 :e20221435. doi:10.1084/jem.20221435 37326974
39 Gurtner A, Borrelli C, Gonzalez-Perez I, Bach K, Acar IE, Núñez NG, Crepaz D, Handler K, Vu VP, Lafzi A, Stirm K, Raju D, Gschwend J, Basler K, Schneider C, Slack E, Valenta T, Becher B, Krebs P, Moor AE, Arnold IC. 2023. Active eosinophils regulate host defence and immune responses in colitis. Nature 615 :151–157. doi:10.1038/s41586-022-05628-7 36509106
40 Mattoo S, Yuk MH, Huang LL, Miller JF. 2004. Regulation of type III secretion in Bordetella. Mol Microbiol 52 :1201–1214. doi:10.1111/j.1365-2958.2004.04053.x 15130135
41 Ahuja U, Shokeen B, Cheng N, Cho Y, Blum C, Coppola G, Miller JF. 2016. Differential regulation of type III secretion and virulence genes in Bordetella pertussis and Bordetella bronchiseptica by a secreted anti-σ factor. Proc Natl Acad Sci U S A 113 :2341–2348. doi:10.1073/pnas.1600320113 26884180
42 Gestal MC, Howard LK, Dewan K, Johnson HM, Barbier M, Bryant C, Soumana IH, Rivera I, Linz B, Blas-Machado U, Harvill ET. 2019. Enhancement of immune response against Bordetella spp. by disrupting immunomodulation. Sci Rep 9 :20261. doi:10.1038/s41598-019-56652-z 31889098
43 Rosenberg HF, Dyer KD, Foster PS. 2013. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13 :9–22. doi:10.1038/nri3341 23154224
44 Cline MJ. 1972. Microbicidal activity of human eosinophils. J Reticuloendothel Soc 12 :332–339.4627531
45 Cline MJ, Hanifin J, Lehrer RI. 1968. Phagocytosis by human eosinophils. Blood 32 :922–934. doi:10.1182/blood.V32.6.922.922 4881979
46 Simon H-U, Yousefi S, Germic N, Arnold IC, Haczku A, Karaulov AV, Simon D, Rosenberg HF. 2020. The cellular functions of eosinophils: collegium internationale allergologicum (CIA) update 2020. Int Arch Allergy Immunol 181 :11–23. doi:10.1159/000504847 31786573
47 Shah K, Ignacio A, McCoy KD, Harris NL. 2020. The emerging roles of eosinophils in mucosal homeostasis. Mucosal Immunol 13 :574–583. doi:10.1038/s41385-020-0281-y 32157190
48 Weller PF, Spencer LA. 2017. Functions of tissue-resident eosinophils. Nat Rev Immunol 17 :746–760. doi:10.1038/nri.2017.95 28891557
49 Lee JJ, Jacobsen EA, McGarry MP, Schleimer RP, Lee NA. 2010. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy 40 :563–575. doi:10.1111/j.1365-2222.2010.03484.x 20447076
50 Shamri R, Xenakis JJ, Spencer LA. 2011. Eosinophils in innate immunity: an evolving story. Cell Tissue Res 343 :57–83. doi:10.1007/s00441-010-1049-6 21042920
51 Chojnacki A, Wojcik K, Petri B, Aulakh G, Jacobsen EA, LeSuer WE, Colarusso P, Patel KD. 2019. Intravital imaging allows real-time characterization of tissue resident eosinophils. Commun Biol 2 :181. doi:10.1038/s42003-019-0425-3 31098414
52 Gupta S, Ross GD, Good RA, Siegal FP. 1976. Surface markers of human eosinophils. Blood 48 :755–763. doi:10.1182/blood.V48.5.755.755 974267
53 Kvarnhammar AM, Cardell LO. 2012. Pattern-recognition receptors in human eosinophils. Immunology 136 :11–20. doi:10.1111/j.1365-2567.2012.03556.x 22242941
54 Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K, Ohta K, Yamamoto K, Hirai K. 2003. Expression and function of toll-like receptors in eosinophils: activation by toll-like receptor 7 ligand. J Immunol 171 :3977–3982. doi:10.4049/jimmunol.171.8.3977 14530316
55 Ehrens A, Rüdiger N, Heepmann L, Linnemann L, Hartmann W, Hübner MP, Breloer M. 2021. Eosinophils and neutrophils eliminate migrating Strongyloides ratti larvae at the site of infection in the context of extracellular DNA trap formation. Front Immunol 12 :715766. doi:10.3389/fimmu.2021.715766 34475874
56 Curran CS, Bertics PJ. 2011. Human eosinophils express RAGE, produce RAGE ligands, exhibit PKC-delta phosphorylation and enhanced viability in response to the RAGE ligand, S100B. Int Immunol 23 :713–728. doi:10.1093/intimm/dxr083 22025532
57 Kvarnhammar AM, Petterson T, Cardell LO. 2011. NOD-like receptors and RIG-I-like receptors in human eosinophils: activation by NOD1 and NOD2 agonists. Immunology 134 :314–325. doi:10.1111/j.1365-2567.2011.03492.x 21978001
58 Borrelli C, Gurtner A, Arnold IC, Moor AE. 2024. Stress-free single-cell transcriptomic profiling and functional genomics of murine eosinophils. Nat Protoc 19 :1679–1709. doi:10.1038/s41596-024-00967-3 38504138
59 Dolitzky A, Shapira G, Grisaru-Tal S, Hazut I, Avlas S, Gordon Y, Itan M, Shomron N, Munitz A. 2021. Transcriptional profiling of mouse eosinophils identifies distinct gene signatures following cellular activation. Front Immunol 12 :802839. doi:10.3389/fimmu.2021.802839 34970274
60 Mills CD. 2012. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol 32 :463–488. doi:10.1615/critrevimmunol.v32.i6.10 23428224
61 Roviezzo F, Del Galdo F, Abbate G, Bucci M, D’Agostino B, Antunes E, De Dominicis G, Parente L, Rossi F, Cirino G, De Palma R. 2004. Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate. Proc Natl Acad Sci U S A 101 :11170–11175. doi:10.1073/pnas.0401439101 15254297
62 Acharya KR, Ackerman SJ. 2014. Eosinophil granule proteins: form and function. J Biol Chem 289 :17406–17415. doi:10.1074/jbc.R113.546218 24802755
63 Aoki A, Hirahara K, Kiuchi M, Nakayama T. 2021. Eosinophils: cells known for over 140 years with broad and new functions. Allergol Int 70 :3–8. doi:10.1016/j.alit.2020.09.002 33032901
64 Willetts L, Felix LC, Jacobsen EA, Puttagunta L, Condjella RM, Zellner KR, Ochkur SI, Kim JD, Luo H, Lee NA, Lee JJ, Moqbel R, Lacy P. 2018. Vesicle-associated membrane protein 7-mediated eosinophil degranulation promotes allergic airway inflammation in mice. Commun Biol 1 :83. doi:10.1038/s42003-018-0081-z 30271964
65 Fettrelet T, Gigon L, Karaulov A, Yousefi S, Simon HU. 2021. The enigma of eosinophil degranulation. Int J Mol Sci 22 :7091. doi:10.3390/ijms22137091 34209362
66 Erjefält JS, Greiff L, Andersson M, Adelroth E, Jeffery PK, Persson CG. 2001. Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease. Thorax 56 :341–344. doi:10.1136/thorax.56.5.341 11312400
67 Aegerter H, Smole U, Heyndrickx I, Verstraete K, Savvides SN, Hammad H, Lambrecht BN. 2021. Charcot-Leyden crystals and other protein crystals driving type 2 immunity and allergy. Curr Opin Immunol 72 :72–78. doi:10.1016/j.coi.2021.03.013 33873124
68 Melo RCN, Wang H, Silva TP, Imoto Y, Fujieda S, Fukuchi M, Miyabe Y, Hirokawa M, Ueki S, Weller PF. 2020. Galectin-10, the protein that forms Charcot-Leyden crystals, is not stored in granules but resides in the peripheral cytoplasm of human eosinophils. J Leukoc Biol 108 :139–149. doi:10.1002/JLB.3AB0220-311R 32108369
69 Heyndrickx I, Deswarte K, Verstraete K, Verschueren KHG, Smole U, Aegerter H, Dansercoer A, Hammad H, Savvides SN, Lambrecht BN. 2024. Ym1 protein crystals promote type 2 immunity. Elife 12 :RP90676. doi:10.7554/eLife.90676 38194250
70 Curchoe CL. 2020. All models are wrong, but some are useful. J Assist Reprod Genet 37 :2389–2391. doi:10.1007/s10815-020-01895-3 33026558
71 Wechsler ME, Munitz A, Ackerman SJ, Drake MG, Jackson DJ, Wardlaw AJ, Dougan SK, Berdnikovs S, Schleich F, Matucci A, Chanez P, Prazma CM, Howarth P, Weller PF, Merkel PA. 2021. Eosinophils in health and disease: a state-of-the-art review. Mayo Clin Proc 96 :2694–2707. doi:10.1016/j.mayocp.2021.04.025 34538424
72 Nelson RK, Bush A, Stokes J, Nair P, Akuthota P. 2020. Eosinophilic asthma. J Allergy Clin Immunol Pract 8 :465–473. doi:10.1016/j.jaip.2019.11.024 31786254
73 Fujieda S, Imoto Y, Kato Y, Ninomiya T, Tokunaga T, Tsutsumiuchi T, Yoshida K, Kidoguchi M, Takabayashi T. 2019. Eosinophilic chronic rhinosinusitis. Allergol Int 68 :403–412. doi:10.1016/j.alit.2019.07.002 31402319
74 Rochman Y, Kotliar M, Ben-Baruch Morgenstern N, Barski A, Wen T, Rothenberg ME. 2023. TSLP shapes the pathogenic responses of memory CD4+ T cells in eosinophilic esophagitis. Sci Signal 16 :eadg6360. doi:10.1126/scisignal.adg6360 37699081
75 Abel-Fernández E, Fernández-Caldas E. 2023. Allergy to fungi: advances in the understanding of fungal allergens. Mol Immunol 163 :216–223. doi:10.1016/j.molimm.2023.09.017 37864931
76 Patel G, Greenberger PA. 2019. Allergic bronchopulmonary aspergillosis. Allergy Asthma Proc 40 :421–424. doi:10.2500/aap.2019.40.4262 31690385
77 Galioto AM, Hess JA, Nolan TJ, Schad GA, Lee JJ, Abraham D. 2006. Role of eosinophils and neutrophils in innate and adaptive protective immunity to larval Strongyloides stercoralis in mice. Infect Immun 74 :5730–5738. doi:10.1128/IAI.01958-05 16988250
78 Huang L, Appleton JA. 2016. Eosinophils in helminth infection: defenders and dupes. Trends Parasitol 32 :798–807. doi:10.1016/j.pt.2016.05.004 27262918
79 Huang Lu, Gebreselassie NG, Gagliardo LF, Ruyechan MC, Lee NA, Lee JJ, Appleton JA. 2014. Eosinophil-derived IL-10 supports chronic nematode infection. J Immunol 193 :4178–4187. doi:10.4049/jimmunol.1400852 25210122
80 Fabre V, Beiting DP, Bliss SK, Gebreselassie NG, Gagliardo LF, Lee NA, Lee JJ, Appleton JA. 2009. Eosinophil deficiency compromises parasite survival in chronic nematode infection. J Immunol 182 :1577–1583. doi:10.4049/jimmunol.182.3.1577 19155506
81 Obata-Ninomiya K, Domeier PP, Ziegler SF. 2020. Basophils and eosinophils in nematode infections. Front Immunol 11 :583824. doi:10.3389/fimmu.2020.583824 33335529
82 Huang L, Beiting DP, Gebreselassie NG, Gagliardo LF, Ruyechan MC, Lee NA, Lee JJ, Appleton JA. 2015. Eosinophils and IL-4 support nematode growth coincident with an innate response to tissue injury. PLoS Pathog 11 :e1005347. doi:10.1371/journal.ppat.1005347 26720604
83 Mickenberg ID, Root RK, Wolff SM. 1972. Bactericidal and metabolic properties of human eosinophils. Blood 39 :67–80.4550469
84 Baehner RL, Johnston RB. 1971. Metabolic and bactericidal activities of human eosinophils. Br J Haematol 20 :277–285. doi:10.1111/j.1365-2141.1971.tb07038.x 5552359
85 Rodríguez NE, Wilson ME. 2014. Eosinophils and mast cells in leishmaniasis. Immunol Res 59 :129–141. doi:10.1007/s12026-014-8536-x 24838146
86 LeMessurier KS, Samarasinghe AE. 2019. Eosinophils: nemeses of pulmonary pathogens? Curr Allergy Asthma Rep 19 :36. doi:10.1007/s11882-019-0867-1 31218528
87 Arita M. 2016. Eosinophil polyunsaturated fatty acid metabolism and its potential control of inflammation and allergy. Allergol Int 65 Suppl :S2–S5. doi:10.1016/j.alit.2016.05.010 27371965
88 Arita M. 2012. Mediator lipidomics in acute inflammation and resolution. J Biochem 152 :313–319. doi:10.1093/jb/mvs092 22923733
89 Isobe Y, Kato T, Arita M. 2012. Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation. Front Immunol 3 :270. doi:10.3389/fimmu.2012.00270 22973272
90 Wen T, Rothenberg ME. 2016. The regulatory function of eosinophils. Microbiol Spectr 4 . doi:10.1128/microbiolspec.MCHD-0020-2015
91 Jacobsen EA, Jackson DJ, Heffler E, Mathur SK, Bredenoord AJ, Pavord ID, Akuthota P, Roufosse F, Rothenberg ME. 2021. Eosinophil knockout humans: uncovering the role of eosinophils through eosinophil-directed biological therapies. Annu Rev Immunol 39 :719–757. doi:10.1146/annurev-immunol-093019-125918 33646859
92 Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone G, Mattei F, Marone G, Schiavoni G. 2018. Eosinophils: the unsung heroes in cancer? Oncoimmunology 7 :e1393134. doi:10.1080/2162402X.2017.1393134 29308325
93 Tiwary M, Rooney RJ, Liedmann S, LeMessurier KS, Samarasinghe AE. 2021. Eosinophil responses at the airway epithelial barrier during the early phase of influenza A virus infection in C57BL/6 mice. Cells 10 :509. doi:10.3390/cells10030509 33673645
94 Fallegger A, Priola M, Artola-Borán M, Núñez NG, Wild S, Gurtner A, Becher B, Yousefi S, Simon H-U, Arnold IC, Müller A. 2022. TGF-β production by eosinophils drives the expansion of peripherally induced neuropilin- RORγt+ regulatory T-cells during bacterial and allergen challenge. Mucosal Immunol 15 :504–514. doi:10.1038/s41385-022-00484-0 35169233
95 Berek C. 2018. Eosinophils can more than kill. J Exp Med 215 :1967–1969. doi:10.1084/jem.20181152 30026193
96 Hosoki K, Nakamura A, Nagao M, Hiraguchi Y, Tanida H, Tokuda R, Wada H, Nobori T, Suga S, Fujisawa T. 2012. Staphylococcus aureus directly activates eosinophils via platelet-activating factor receptor. J Leukoc Biol 92 :333–341. doi:10.1189/jlb.0112009 22595142
97 Hatano Y, Taniuchi S, Masuda M, Tsuji S, Ito T, Hasui M, Kobayashi Y, Kaneko K. 2009. Phagocytosis of heat-killed Staphylococcus aureus by eosinophils: comparison with neutrophils. APMIS 117 :115–123. doi:10.1111/j.1600-0463.2008.00022.x 19239433
98 Williams TL, Rada B, Tandon E, Gestal MC. 2020. “NETs and EETs, a whole web of mess”. Microorganisms 8 :1925. doi:10.3390/microorganisms8121925 33291570
99 Yousefi S, Simon D, Stojkov D, Karsonova A, Karaulov A, Simon HU. 2020. In vivo evidence for extracellular DNA trap formation. Cell Death Dis 11 :300. doi:10.1038/s41419-020-2497-x 32355207
100 Zeck-Kapp G, Kroegel C, Riede UN, Kapp A. 1995. Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. Allergy 50 :34–47. doi:10.1111/j.1398-9995.1995.tb02481.x
101 Arnold IC. 2022. Adapting to their new home: eosinophils remodel the gut architecture. J Exp Med 219 :e20220146. doi:10.1084/jem.20220146 35315912
102 Dunn JLM, Caldwell JM, Ballaban A, Ben-Baruch Morgenstern N, Rochman M, Rothenberg ME. 2021. Bidirectional crosstalk between eosinophils and esophageal epithelial cells regulates inflammatory and remodeling processes. Mucosal Immunol 14 :1133–1143. doi:10.1038/s41385-021-00400-y 33972688
103 Travers J, Rothenberg ME. 2015. Eosinophils in mucosal immune responses. Mucosal Immunol 8 :464–475. doi:10.1038/mi.2015.2 25807184
104 Cafone J, Ruffner MA, Spergel JM. 2020. The role of eosinophils in immunotherapy. Curr Opin Allergy Clin Immunol 20 :329. doi:10.1097/ACI.0000000000000617
105 Jacobsen EA, Zellner KR, Colbert D, Lee NA, Lee JJ. 2011. Eosinophils regulate dendritic cells and Th2 pulmonary immune responses following allergen provocation. J Immunol 187 :6059–6068. doi:10.4049/jimmunol.1102299 22048766
106 Xenakis JJ, Howard ED, Smith KM, Olbrich CL, Huang Y, Anketell D, Maldonado S, Cornwell EW, Spencer LA. 2018. Resident intestinal eosinophils constitutively express antigen presentation markers and include two phenotypically distinct subsets of eosinophils. Immunology 154 :298–308. doi:10.1111/imm.12885 29281125
107 Farhan RK, Vickers MA, Ghaemmaghami AM, Hall AM, Barker RN, Walsh GM. 2016. Effective antigen presentation to helper T cells by human eosinophils. Immunology 149 :413–422. doi:10.1111/imm.12658 27502559
108 Padigel UM, Hess JA, Lee JJ, Lok JB, Nolan TJ, Schad GA, Abraham D. 2007. Eosinophils act as antigen-presenting cells to induce immunity to Strongyloides stercoralis in mice. J Infect Dis 196 :1844–1851. doi:10.1086/522968 18190266
109 Samarasinghe AE, Melo RCN, Duan S, LeMessurier KS, Liedmann S, Surman SL, Lee JJ, Hurwitz JL, Thomas PG, McCullers JA. 2017. Eosinophils promote antiviral immunity in mice infected with influenza A virus. J Immunol 198 :3214–3226. doi:10.4049/jimmunol.1600787 28283567
110 Padigel U.M, Lee JJ, Nolan TJ, Schad GA, Abraham D. 2006. Eosinophils can function as antigen-presenting cells to induce primary and secondary immune responses to Strongyloides stercoralis. Infect Immun 74 :3232–3238. doi:10.1128/IAI.02067-05 16714550
111 Prince L, Martín-Faivre L, Villeret B, Sanchez-Guzman D, Le Guen P, Sallenave J-M, Garcia-Verdugo I. 2023. Eosinophils recruited during pulmonary vaccination regulate mucosal antibody production. Am J Respir Cell Mol Biol 68 :186–200. doi:10.1165/rcmb.2022-0236OC 36194580
112 August A, Marichal T. 2023. Eosinophils and lung mucosal antibody production: is location the key? Am J Respir Cell Mol Biol 68 :124–126. doi:10.1165/rcmb.2022-0410ED 36306503
113 Linz B, Ivanov YV, Preston A, Brinkac L, Parkhill J, Kim M, Harris SR, Goodfield LL, Fry NK, Gorringe AR, Nicholson TL, Register KB, Losada L, Harvill ET. 2016. Acquisition and loss of virulence-associated factors during genome evolution and speciation in three clades of Bordetella species. BMC Genomics 17 :767. doi:10.1186/s12864-016-3112-5 27716057
114 Weigand MR, Peng Y, Loparev V, Batra D, Bowden KE, Burroughs M, Cassiday PK, Davis JK, Johnson T, Juieng P, Knipe K, Mathis MH, Pruitt AM, Rowe L, Sheth M, Tondella ML, Williams MM. 2017. The history of Bordetella pertussis genome evolution includes structural rearrangement. J Bacteriol 199 :e00806-16. doi:10.1128/JB.00806-16 28167525
115 Martínez de Tejada G, Miller JF, Cotter PA. 1996. Comparative analysis of the virulence control systems of Bordetella pertussis and Bordetella bronchiseptica. Mol Microbiol 22 :895–908. doi:10.1046/j.1365-2958.1996.01538.x 8971711
116 Taylor-Mulneix DL, Hamidou Soumana I, Linz B, Harvill ET. 2017. Evolution of Bordetellae from environmental microbes to human respiratory pathogens: amoebae as a missing link. Front Cell Infect Microbiol 7 :510. doi:10.3389/fcimb.2017.00510 29322035
117 Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Harris DE, Holden MTG, Churcher CM, Bentley SD, Mungall KL, et al. . 2003. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 35 :32–40. doi:10.1038/ng1227 12910271
118 Aricò B, Gross R, Smida J, Rappuoli R. 1987. Evolutionary relationships in the genus Bordetella. Mol Microbiol 1 :301–308. doi:10.1111/j.1365-2958.1987.tb01936.x 2896289
119 Badhai J, Das SK. 2023. Genomic evidence and virulence properties decipher the extra-host origin of Bordetella bronchiseptica. J Appl Microbiol 134 :lxad200. doi:10.1093/jambio/lxad200 37660236
120 Harvill ET, Cotter PA, Miller JF. 1999. Pregenomic comparative analysis between Bordetella bronchiseptica RB50 and Bordetella pertussis Tohama I in murine models of respiratory tract infection. Infect Immun 67 :6109–6118. doi:10.1128/IAI.67.11.6109-6118.1999 10531274
121 Soumana IH, Linz B, Dewan KK, Sarr D, Gestal MC, Howard LK, Caulfield AD, Rada B, Harvill ET. 2021. Modeling immune evasion and vaccine limitations by targeted nasopharyngeal Bordetella pertussis inoculation in mice. Emerg Infect Dis 27 :2107–2116. doi:10.3201/eid2708.203566 34286682
122 Soumana IH, Dewan KK, Linz B, Rivera I, Ma L, Howard LK, Caulfield AD, Sedney CJ, Blas-Machado U, Sebo P, Harvill ET. 2022. Modeling the catarrhal stage of Bordetella pertussis upper respiratory tract infections in mice. Dis Model Mech 15 :dmm049266. doi:10.1242/dmm.049266 35311902
123 First NJ, Pedreira-Lopez J, San-Silvestre MRF, Parrish KM, Lu XH, Gestal MC. 2023. Bordetella spp. utilize the type 3 secretion system to manipulate the VIP/VPAC2 signaling and promote colonization and persistence of the three classical. Front Cell Infect Microbiol 13 :1111502. doi:10.3389/fcimb.2023.1111502 37065208
124 Bendor L, Weyrich LS, Linz B, Rolin OY, Taylor DL, Goodfield LL, Smallridge WE, Kennett MJ, Harvill ET. 2015. Type six secretion system of Bordetella bronchiseptica and adaptive immune components limit intracellular survival during infection. PLoS One 10 :e0140743. doi:10.1371/journal.pone.0140743 26485303
125 Bart MJ, van Gent M, van der Heide HGJ, Boekhorst J, Hermans P, Parkhill J, Mooi FR. 2010. Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics 11 :627. doi:10.1186/1471-2164-11-627 21070624
126 Luu LDW, Zhong L, Kaur S, Raftery MJ, Lan R. 2021. Comparative phosphoproteomics of classical Bordetellae elucidates the potential role of serine, threonine and tyrosine phosphorylation in Bordetella biology and virulence. Front Cell Infect Microbiol 11 :660280. doi:10.3389/fcimb.2021.660280 33928046
127 Bayram J, Malcova I, Sinkovec L, Holubova J, Streparola G, Jurnecka D, Kucera J, Sedlacek R, Sebo P, Kamanova J. 2020. Cytotoxicity of the effector protein BteA was attenuated in Bordetella pertussis by insertion of an alanine residue. PLoS Pathog 16 :e1008512. doi:10.1371/journal.ppat.1008512 32776984
128 Yuk MH, Cotter PA, Miller JF. 1996. Genetic regulation of airway colonization by Bordetella species. Am J Respir Crit Care Med 154 :S150–S154. doi:10.1164/ajrccm/154.4_Pt_2.S150 8876534
129 Belcher T, Dubois V, Rivera-Millot A, Locht C, Jacob-Dubuisson F. 2021. Pathogenicity and virulence of Bordetella pertussis and its adaptation to its strictly human host. Virulence 12 :2608–2632. doi:10.1080/21505594.2021.1980987 34590541
130 Hewlett EL, Burns DL, Cotter PA, Harvill ET, Merkel TJ, Quinn CP, Stibitz ES. 2014. Pertussis pathogenesis--what we know and what we don't know. J Infect Dis 209 :982–985. doi:10.1093/infdis/jit639 24626533
131 Melvin JA, Scheller EV, Miller JF, Cotter PA. 2014. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol 12 :274–288. doi:10.1038/nrmicro3235 24608338
132 Cotter PA, Miller JF. 1996. Genetic analysis of the Bordetella-host interaction. Ann N Y Acad Sci 797 :65–76. doi:10.1111/j.1749-6632.1996.tb52950.x 8993352
133 Cotter PA, Yuk MH, Mattoo S, Akerley BJ, Boschwitz J, Relman DA, Miller JF. 1998. Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization. Infect Immun 66 :5921–5929. doi:10.1128/IAI.66.12.5921-5929.1998 9826374
134 Rodríguez ME, Hellwig SMM, Pérez Vidakovics MLA, Berbers GAM, van de Winkel JGJ. 2006. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies. FEMS Immunol Med Microbiol 46 :39–47. doi:10.1111/j.1574-695X.2005.00001.x 16420595
135 Mattoo S, Miller JF, Cotter PA. 2000. Role of Bordetella bronchiseptica fimbriae in tracheal colonization and development of a humoral immune response. Infect Immun 68 :2024–2033. doi:10.1128/IAI.68.4.2024-2033.2000 10722598
136 Emsley P, Charles IG, Fairweather NF, Isaacs NW. 1996. Structure of Bordetella pertussis virulence factor P.69 pertactin. Nature 381 :90–92. doi:10.1038/381090a0 8609998
137 Witvliet MH, Burns DL, Brennan MJ, Poolman JT, Manclark CR. 1989. Binding of pertussis toxin to eucaryotic cells and glycoproteins. Infect Immun 57 :3324–3330. doi:10.1128/iai.57.11.3324-3330.1989 2478471
138 Bassinet L, Gueirard P, Maitre B, Housset B, Gounon P, Guiso N. 2000. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis. Infect Immun 68 :1934–1941. doi:10.1128/IAI.68.4.1934-1941.2000 10722585
139 Guermonprez P, Khelef N, Blouin E, Rieu P, Ricciardi-Castagnoli P, Guiso N, Ladant D, Leclerc C. 2001. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the αMβ2 integrin (Cd11b/Cd18). J Exp Med 193 :1035–1044. doi:10.1084/jem.193.9.1035 11342588
140 Perez Vidakovics MLA, Lamberti Y, van der Pol W-L, Yantorno O, Rodriguez ME. 2006. Adenylate cyclase influences filamentous haemagglutinin-mediated attachment of Bordetella pertussis to epithelial alveolar cells. FEMS Immunol Med Microbiol 48 :140–147. doi:10.1111/j.1574-695X.2006.00136.x 16965362
141 Hasan S, Kulkarni NN, Asbjarnarson A, Linhartova I, Osicka R, Sebo P, Gudmundsson GH. 2018. Bordetella pertussis adenylate cyclase toxin disrupts functional integrity of bronchial epithelial layers. Infect Immun 86 :e00445-17. doi:10.1128/IAI.00445-17 29203545
142 Bassinet L, Fitting C, Housset B, Cavaillon JM, Guiso N. 2004. Bordetella pertussis adenylate cyclase-hemolysin induces interleukin-6 secretion by human tracheal epithelial cells. Infect Immun 72 :5530–5533. doi:10.1128/IAI.72.9.5530-5533.2004 15322060
143 French CT, Panina EM, Yeh SH, Griffith N, Arambula DG, Miller JF. 2009. The Bordetella type III secretion system effector BteA contains a conserved N-terminal motif that guides bacterial virulence factors to lipid rafts. Cell Microbiol 11 :1735–1749. doi:10.1111/j.1462-5822.2009.01361.x 19650828
144 Lamberti YA, Hayes JA, Perez Vidakovics ML, Harvill ET, Rodriguez ME. 2010. Intracellular trafficking of Bordetella pertussis in human macrophages. Infect Immun 78 :907–913. doi:10.1128/IAI.01031-09 20065021
145 Carbonetti NH, Artamonova GV, Van Rooijen N, Ayala VI. 2007. Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect Immun 75 :1713–1720. doi:10.1128/IAI.01578-06 17242062
146 Wan M, Zhou Y, Zhu Y. 2018. Subversion of macrophage functions by bacterial protein toxins and effectors. Curr Issues Mol Biol 25 :61–80. doi:10.21775/cimb.025.061 28875940
147 Aderem A, Underhill DM. 1999. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 17 :593–623. doi:10.1146/annurev.immunol.17.1.593 10358769
148 Wang S, Parhar K, Chiu K, Tran A, Gangoiti P, Kong J, Gonzalez M, Salh B, Duronio V, Steinbrecher U. 2007. Pertussis toxin promotes macrophage survival through inhibition of acid sphingomyelinase and activation of the phosphoinositide 3-kinase/protein kinase B pathway. Cell Signal 19 :1772–1783. doi:10.1016/j.cellsig.2007.04.001 17521884
149 Boyd AP, Ross PJ, Conroy H, Mahon N, Lavelle EC, Mills KHG. 2005. Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death. J Immunol 175 :730–738. doi:10.4049/jimmunol.175.2.730 16002668
150 Saukkonen K, Cabellos C, Burroughs M, Prasad S, Tuomanen E. 1991. Integrin-mediated localization of Bordetella pertussis within macrophages: role in pulmonary colonization. J Exp Med 173 :1143–1149. doi:10.1084/jem.173.5.1143 2022924
151 Bumba L, Masin J, Fiser R, Sebo P. 2010. Bordetella adenylate cyclase toxin mobilizes its β2 integrin receptor into lipid rafts to accomplish translocation across target cell membrane in two steps. PLoS Pathog 6 :e1000901. doi:10.1371/journal.ppat.1000901 20485565
152 Ahmad JN, Holubova J, Benada O, Kofronova O, Stehlik L, Vasakova M, Sebo P. 2019. Adenylate cyclase toxin inhibits monocyte-to-macrophage transition and dedifferentiates human alveolar macrophages into monocyte-like cells. mBio 10 :e01743-19. doi:10.1128/mBio.01743-19 31551332
153 Andreasen C, Carbonetti NH. 2008. Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice. Infect Immun 76 :5139–5148. doi:10.1128/IAI.00895-08 18765723
154 Spangrude GJ, Sacchi F, Hill HR, Van Epps DE, Daynes RA. 1985. Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin. J Immunol 135 :4135–4143.2999238
155 Vojtova J, Kamanova J, Sebo P. 2006. Bordetella adenylate cyclase toxin: a swift saboteur of host defense. Curr Opin Microbiol 9 :69–75. doi:10.1016/j.mib.2005.12.011 16406775
156 McGuirk P, Mills KHG. 2000. Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur J Immunol 30 :415–422. doi:10.1002/1521-4141(200002)30:2<415::AID-IMMU415>3.0.CO;2-X 10671196
157 Nagamatsu K, Kuwae A, Konaka T, Nagai S, Yoshida S, Eguchi M, Watanabe M, Mimuro H, Koyasu S, Abe A. 2009. Bordetella evades the host immune system by inducing IL-10 through a type III effector, BopN. J Exp Med 206 :3073–3088. doi:10.1084/jem.20090494 20008527
158 Kuwae A, Momose F, Nagamatsu K, Suyama Y, Abe A. 2016. BteA secreted from the Bordetella bronchiseptica type III secetion system induces necrosis through an actin cytoskeleton signaling pathway and inhibits phagocytosis by macrophages. PLoS One 11 :e0148387. doi:10.1371/journal.pone.0148387 26828590
159 Fennelly NK, Sisti F, Higgins SC, Ross PJ, van der Heide H, Mooi FR, Boyd A, Mills KHG. 2008. Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun 76 :1257–1266. doi:10.1128/IAI.00836-07 18195025
160 Nicholson TL, Brockmeier SL, Loving CL, Register KB, Kehrli ME, Shore SM. 2014. The Bordetella bronchiseptica type III secretion system is required for persistence and disease severity but not transmission in swine. Infect Immun 82 :1092–1103. doi:10.1128/IAI.01115-13 24366249
161 Nicosia A, Perugini M, Franzini C, Casagli MC, Borri MG, Antoni G, Almoni M, Neri P, Ratti G, Rappuoli R. 1986. Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. Proc Natl Acad Sci U S A 83 :4631–4635. doi:10.1073/pnas.83.13.4631 2873570
162 Monack DM, Arico B, Rappuoli R, Falkow S. 1989. Phase variants of Bordetella bronchiseptica arise by spontaneous deletions in the vir locus. Mol Microbiol 3 :1719–1728. doi:10.1111/j.1365-2958.1989.tb00157.x 2560120
163 Gross R, Rappuoli R. 1988. Positive regulation of pertussis toxin expression. Proc Natl Acad Sci U S A 85 :3913–3917. doi:10.1073/pnas.85.11.3913 2897691
164 Weiss AA, Hewlett EL, Myers GA, Falkow S. 1983. Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect Immun 42 :33–41. doi:10.1128/iai.42.1.33-41.1983 6311749
165 Weiss AA, Falkow S. 1983. Transposon insertion and subsequent donor formation promoted by Tn501 in Bordetella pertussis. J Bacteriol 153 :304–309. doi:10.1128/jb.153.1.304-309.1983 6294051
166 Weiss AA, Falkow S. 1982. Plasmid transfer to Bordetella pertussis: conjugation and transformation. J Bacteriol 152 :549–552. doi:10.1128/jb.152.1.549-552.1982 6288667
167 Stibitz S, Aaronson W, Monack D, Falkow S. 1988. The vir locus and phase-variation in Bordetella pertussis. Tokai J Exp Clin Med 13 Suppl :223–226.2908523
168 Isberg RR, Falkow S. 1985. Genetic analysis of bacterial virulence determinants in Bordetella pertussis and the pathogenetic Yersinia. Curr Top Microbiol Immunol 118 :1–11. doi:10.1007/978-3-642-70586-1_1
169 Miller JF, Mekalanos JJ, Falkow S. 1989. Coordinate regulation and sensory transduction in the control of bacterial virulence. Science 243 :916–922. doi:10.1126/science.2537530 2537530
170 Miller JF, Roy CR, Falkow S. 1989. Analysis of Bordetella pertussis virulence gene regulation by use of transcriptional fusions in Escherichia coli. J Bacteriol 171 :6345–6348. doi:10.1128/jb.171.11.6345-6348.1989 2553678
171 Miller JF, Johnson SA, Black WJ, Beattie DT, Mekalanos JJ, Falkow S. 1992. Constitutive sensory transduction mutations in the Bordetella pertussis bvgS gene. J Bacteriol 174 :970–979. doi:10.1128/jb.174.3.970-979.1992 1732230
172 Moon K, Sim M, Tai C-H, Yoo K, Merzbacher C, Yu S-H, Kim DD, Lee J, Förstner KU, Chen Q, Stibitz S, Knipling LG, Hinton DM. 2021. Identification of BvgA-dependent and BvgA-independent small RNAs (sRNAs) in Bordetella pertussis using the prokaryotic sRNA prediction toolkit ANNOgesic. Microbiol Spectr 9 :e0004421. doi:10.1128/Spectrum.00044-21 34550019
173 Weiss DS, Brotcke A, Henry T, Margolis JJ, Chan K, Monack DM. 2007. In vivo negative selection screen identifies genes required for Francisella virulence. Proc Natl Acad Sci U S A 104 :6037–6042. doi:10.1073/pnas.0609675104 17389372
174 Schneider OD, Weiss AA, Miller WE. 2007. Pertussis toxin utilizes proximal components of the T-cell receptor complex to initiate signal transduction events in T cells. Infect Immun 75 :4040–4049. doi:10.1128/IAI.00414-07 17562776
175 Weiss AA, Patton AK, Millen SH, Chang SJ, Ward JI, Bernstein DI. 2004. Acellular pertussis vaccines and complement killing of Bordetella pertussis. Infect Immun 72 :7346–7351. doi:10.1128/IAI.72.12.7346-7351.2004 15557666
176 Roy CR, Miller JF, Falkow S. 1989. The bvgA gene of Bordetella pertussis encodes a transcriptional activator required for coordinate regulation of several virulence genes. J Bacteriol 171 :6338–6344. doi:10.1128/jb.171.11.6338-6344.1989 2553677
177 Zimna K, Medina E, Jungnitz H, Guzmán CA. 2001. Role played by the response regulator Ris in Bordetella bronchiseptica resistance to macrophage killing. FEMS Microbiol Lett 201 :177–180. doi:10.1111/j.1574-6968.2001.tb10753.x 11470358
178 Jungnitz H, West NP, Walker MJ, Chhatwal GS, Guzmán CA. 1998. A second two-component regulatory system of Bordetella bronchiseptica required for bacterial resistance to oxidative stress, production of acid phosphatase, and in vivo persistence. Infect Immun 66 :4640–4650. doi:10.1128/IAI.66.10.4640-4650.1998 9746560
179 Bone MA, Wilk AJ, Perault AI, Marlatt SA, Scheller EV, Anthouard R, Chen Q, Stibitz S, Cotter PA, Julio SM. 2017. Bordetella PlrSR regulatory system controls BvgAS activity and virulence in the lower respiratory tract. Proc Natl Acad Sci U S A 114 :E1519–E1527. doi:10.1073/pnas.1609565114 28167784
180 Barr SA, Kennedy EN, McKay LS, Johnson RM, Ohr RJ, Cotter PA, Bourret RB. 2023. Phosphorylation chemistry of the Bordetella PlrSR TCS and its contribution to bacterial persistence in the lower respiratory tract. Mol Microbiol 119 :174–190. doi:10.1111/mmi.15019 36577696
181 Bibova I, Skopova K, Masin J, Cerny O, Hot D, Sebo P, Vecerek B. 2013. The RNA chaperone Hfq is required for virulence of Bordetella pertussis. Infect Immun 81 :4081–4090. doi:10.1128/IAI.00345-13 23980112
182 Bibova I, Hot D, Keidel K, Amman F, Slupek S, Cerny O, Gross R, Vecerek B. 2015. Transcriptional profiling of Bordetella pertussis reveals requirement of RNA chaperone Hfq for type III secretion system functionality. RNA Biol 12 :175–185. doi:10.1080/15476286.2015.1017237 25674816
183 Guttman C, Davidov G, Yahalom A, Shaked H, Kolusheva S, Bitton R, Barber-Zucker S, Chill JH, Zarivach R. 2013. BtcA, a class IA type III chaperone, interacts with the BteA N-terminal domain through a globular/non-globular mechanism. PLoS One 8 :e81557. doi:10.1371/journal.pone.0081557 24312558
184 Belhart K, Sisti F, Gestal MC, Fernández J. 2023. Bordetella bronchiseptica diguanylate cyclase BdcB inhibits the type three secretion system and impacts the immune response. Sci Rep 13 :7157. doi:10.1038/s41598-023-34106-x 37130958
185 Hiramatsu Y, Suzuki K, Motooka D, Nakamura S, Horiguchi Y. 2020. Expression of small RNAs of Bordetella pertussis colonizing murine tracheas. Microbiol Immunol 64 :469–475. doi:10.1111/1348-0421.12791 32227523
186 Yount KS, Jennings-Gee J, Caution K, Fullen AR, Corps KN, Quataert S, Deora R, Dubey P. 2019. Colonization factor A (BcfA) elicits protective immunity against Bordetella bronchiseptica in the absence of an additional adjuvant. Infect Immun 87 :00506–00519. doi:10.1128/IAI.00506-19
187 Ma L, Dewan KK, Taylor-Mulneix DL, Wagner SM, Linz B, Rivera I, Su Y, Caulfield AD, Blas-Machado U, Harvill ET. 2021. Pertactin contributes to shedding and transmission of Bordetella bronchiseptica. PLoS Pathog 17 :e1009735. doi:10.1371/journal.ppat.1009735 34347835
188 Moon K, Bonocora RP, Kim DD, Chen Q, Wade JT, Stibitz S, Hinton DM. 2017. The BvgAS regulon of Bordetella pertussis. mBio 8 :e01526-17. doi:10.1128/mBio.01526-17 29018122
189 Gestal MC, Howard LK, Dewan KK, Harvill ET. 2022. BbvAC: a live vaccine candidate that provides long-lasting anamnestic and Th17-mediated immunity against the three classical Bordetella spp. mSphere 7 :e0089221. doi:10.1128/msphere.00892-21 35196124
190 Cohen SG, Sapp TM, Chiampi PN. 1970. Eosinophil leukocyte responses and hypersensitivity reactions in the Bordetella pertussis-treated mouse. J Allergy 46 :205–215. doi:10.1016/0021-8707(70)90024-9 4318636
191 Vandebriel RJ, Gremmer ER, Vermeulen JP, Hellwig SMM, Dormans JAMA, Roholl PJM, Mooi FR. 2007. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine 25 :2346–2360. doi:10.1016/j.vaccine.2005.09.062 17224216
192 Rubin K, Glazer S. 2018. The pertussis hypothesis: Bordetella pertussis colonization in the etiology of asthma and diseases of allergic sensitization. Med Hypotheses 120 :101–115. doi:10.1016/j.mehy.2018.08.006 30220328
193 Ennis DP, Cassidy JP, Mahon BP. 2005. Acellular pertussis vaccine protects against exacerbation of allergic asthma due to Bordetella pertussis in a murine model. Clin Diagn Lab Immunol 12 :409–417. doi:10.1128/CDLI.12.3.409-417.2005 15753254
194 Ennis DP, Cassidy JP, Mahon BP. 2005. Whole-cell pertussis vaccine protects against Bordetella pertussis exacerbation of allergic asthma. Immunol Lett 97 :91–100. doi:10.1016/j.imlet.2004.10.011 15626480
195 Ennis DP, Cassidy JP, Mahon BP. 2004. Prior Bordetella pertussis infection modulates allergen priming and the severity of airway pathology in a murine model of allergic asthma. Clin Exp Allergy 34 :1488–1497. doi:10.1111/j.1365-2222.2004.02042.x 15347385
196 Kim YS, Kwon KS, Kim DK, Choi IW, Lee HK. 2004. Inhibition of murine allergic airway disease by Bordetella pertussis. Immunology 112 :624–630. doi:10.1111/j.1365-2567.2004.01880.x 15270734
197 Dong W, Selgrade MK, Gilmour MI. 2003. Systemic administration of Bordetella pertussis enhances pulmonary sensitization to house dust mite in juvenile rats. Toxicol Sci 72 :113–121. doi:10.1093/toxsci/kfg015 12604840
198 Belcher T, Kammoun H, Coutte L, Debrie A-S, Mielcarek N, Sirard J-C, Cauchi S, Locht C. 2022. Live attenuated Bordetella pertussis vaccine candidate BPZE1 transiently protects against lethal pneumococcal disease in mice. Vaccine 40 :1555–1562. doi:10.1016/j.vaccine.2021.01.025 33509692
199 Ammit AJ, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, Krymskaya VP, Kane SA, Peters SP, Penn RB, Spiegel S, Panettieri RA Jr. 2001. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J 15 :1212–1214. doi:10.1096/fj.00-0742fje 11344091
200 Skerry C, Scanlon K, Ardanuy J, Roberts D, Zhang L, Rosen H, Carbonetti NH. 2017. Reduction of pertussis inflammatory pathology by therapeutic treatment with sphingosine-1-phosphate receptor ligands by a pertussis toxin-insensitive mechanism. J Infect Dis 215 :278–286. doi:10.1093/infdis/jiw536 27815382
201 Maguire TJA, Yung S, Ortiz-Zapater E, Kayode OS, Till S, Corrigan C, Siew LQC, Knock GA, Woszczek G. 2023. Sphingosine-1-phosphate induces airway smooth muscle hyperresponsiveness and proliferation. J Allergy Clin Immunol 152 :1131–1140. doi:10.1016/j.jaci.2023.05.028 37474025
202 Athari SS. 2019. Targeting cell signaling in allergic asthma. Signal Transduct Target Ther 4 :45. doi:10.1038/s41392-019-0079-0 31637021
203 Groneberg DA, Springer J, Fischer A. 2001. Vasoactive intestinal polypeptide as mediator of asthma. Pulm Pharmacol Ther 14 :391–401. doi:10.1006/pupt.2001.0306 11603952
204 Nguyen NTD, Pathak AK, Cattadori IM. 2022. Gastrointestinal helminths increase Bordetella bronchiseptica shedding and host variation in supershedding. Elife 11 :e70347. doi:10.7554/eLife.70347 36346138
205 Imaizumi A, Lefort J, Leduc D, Lellouch-Tubiana A, Vargaftig BB. 1992. Pertussis toxin induces bronchopulmonary hyperresponsiveness in guinea-pigs while antagonizing the effects of formyl-L-methionyl-L-leucyl-L-phenylalanine. Eur J Pharmacol 212 :177–186. doi:10.1016/0014-2999(92)90327-Z 1318209
206 Birkebaek NH. 2001. Bordetella pertussis in the aetiology of chronic cough in adults. Diagnostic methods and clinic. Dan Med Bull 48 :77–80.11414122
207 Birkebaek NH, Kristiansen M, Seefeldt T, Degn J, Moller A, Heron I, Andersen PL, Moller JK, Ostergard L. 1999. Bordetella pertussis and chronic cough in adults. Clin Infect Dis 29 :1239–1242. doi:10.1086/313448 10524969
208 Ojetti V, Armuzzi A, De Luca A, Nucera E, Franceschi F, Candelli M, Zannoni GF, Danese S, Di Caro S, Vastola M, Schiavino D, Gasbarrini G, Patriarca G, Pola P, Gasbarrini A. 2001. Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria. Int Arch Allergy Immunol 125 :66–72. doi:10.1159/000053798 11385290
209 Zhang X, Arnold IC, Müller A. 2020. Mechanisms of persistence, innate immune activation and immunomodulation by the gastric pathogen Helicobacter pylori. Curr Opin Microbiol 54 :1–10. doi:10.1016/j.mib.2020.01.003 32007716
210 Ko SH, Jeon JI, Kim Y-J, Yoon HJ, Kim H, Kim N, Kim JS, Kim JM. 2015. Helicobacter pylori outer membrane vesicle proteins induce human eosinophil degranulation via a β2 integrin CD11/CD18- and ICAM-1-dependent mechanism. Mediators Inflamm 2015 :301716. doi:10.1155/2015/301716 25821353
211 Rossi FW, Prevete N, Montuori N, Ragno P, Selleri C, Marone G, de Paulis A. 2012. Hp(2-20) peptide of Helicobacter pylori and the innate immune receptors: specific role(s) of the formyl peptide receptors. Infez Med 20 Suppl 2 :19–25.23042002
212 de Paulis A, Prevete N, Rossi FW, Rivellese F, Salerno F, Delfino G, Liccardo B, Avilla E, Montuori N, Mascolo M, Staibano S, Melillo RM, D’Argenio G, Ricci V, Romano M, Marone G. 2009. Helicobacter pylori Hp(2-20) promotes migration and proliferation of gastric epithelial cells by interacting with formyl peptide receptors in vitro and accelerates gastric mucosal healing in vivo. J Immunol 183 :3761–3769. doi:10.4049/jimmunol.0900863 19692643
213 Johnson KS, Yang C, Carter JE, Worthington AK, Robinson EK, Lopez-Magaña R, Salgado F, Arnold I, Ottemann KM. 2023. Helicobacter pylori chronic-stage inflammation undergoes fluctuations that are altered in tlpA mutants. Infect Immun 91 :e0032222. doi:10.1128/iai.00322-22 36533917
214 Blosse A, Peru S, Levy M, Marteyn B, Floch P, Sifré E, Giese A, Prochazkova-Carlotti M, Azzi Martin L, Dubus P, Mégraud F, Ruskone Fournestraux A, Fabiani B, Copie Bergman C, Robe C, Hahne M, Huard B, Lehours P. 2020. APRIL-producing eosinophils are involved in gastric MALT lymphomagenesis induced by Helicobacter sp infection. Sci Rep 10 :14858. doi:10.1038/s41598-020-71792-3 32908188
215 Rosenberg HF, Masterson JC, Furuta GT. 2016. Eosinophils, probiotics, and the microbiome. J Leukoc Biol 100 :881–888. doi:10.1189/jlb.3RI0416-202R 27549754
216 Doulberis M, Kountouras J, Rogler G. 2020. Reconsidering the "protective" hypothesis of Helicobacter pylori infection in eosinophilic esophagitis. Ann N Y Acad Sci 1481 :59–71. doi:10.1111/nyas.14449 32770542
217 Sonnenberg A, Dellon ES, Turner KO, Genta RM. 2017. The influence of Helicobacter pylori on the ethnic distribution of esophageal eosinophilia. Helicobacter 22 :e12370. doi:10.1111/hel.12370
218 Zuo ZT, Ma Y, Sun Y, Bai CQ, Ling CH, Yuan FL. 2021. The protective effects of Helicobacter pylori infection on allergic asthma. Int Arch Allergy Immunol 182 :53–64. doi:10.1159/000508330 33080611
219 Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Taube C, Müller A. 2011. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 121 :3088–3093. doi:10.1172/JCI45041 21737881
220 Germic N, Hosseini A, Stojkov D, Oberson K, Claus M, Benarafa C, Calzavarini S, Angelillo-Scherrer A, Arnold IC, Müller A, Riether C, Yousefi S, Simon H-U. 2021. ATG5 promotes eosinopoiesis but inhibits eosinophil effector functions. Blood 137 :2958–2969. doi:10.1182/blood.2020010208 33598715
221 Kim J, Kim BE, Ahn K, Leung DYM. 2019. Interactions between atopic dermatitis and Staphylococcus aureus infection: clinical implications. Allergy Asthma Immunol Res 11 :593. doi:10.4168/aair.2019.11.5.593 31332972
222 Prince LR, Graham KJ, Connolly J, Anwar S, Ridley R, Sabroe I, Foster SJ, Whyte MKB. 2012. Staphylococcus aureus induces eosinophil cell death mediated by α-hemolysin. PLoS One 7 :e31506. doi:10.1371/journal.pone.0031506 22355374
223 Matsui K, Wirotesangthong M, Nishikawa A. 2007. Percutaneous application of peptidoglycan from Staphylococcus aureus induces eosinophil infiltration in mouse skin. Clin Exp Allergy 37 :615–622. doi:10.1111/j.1365-2222.2007.02673.x 17430360
224 Gangwar RS, Levi-Schaffer F. 2016. sCD48 is anti-inflammatory in Staphylococcus aureus enterotoxin B-induced eosinophilic inflammation. Allergy 71 :829–839. doi:10.1111/all.12851 26836239
225 Haftu H, Tadese K, Gebrehiwot T, Gebregziabher H. 2020. How common is eosinophilia in tuberculosis? Case report. Pediatric Health Med Ther 11 :59–63. doi:10.2147/PHMT.S244155 32110139
226 Garg G, Gogia A, Kakar A, Miglani P. 2017. Persistent marked peripheral eosinophilia due to tuberculosis: a case report. Iran J Med Sci 42 :102–105.28293059
227 Mayer-Barber KD. 2023. Granulocytes subsets and their divergent functions in host resistance to Mycobacterium tuberculosis - a 'tipping-point' model of disease exacerbation. Curr Opin Immunol 84 :102365. doi:10.1016/j.coi.2023.102365 37437471
228 Bohrer AC, Castro E, Hu Z, Queiroz ATL, Tocheny CE, Assmann M, Sakai S, Nelson C, Baker PJ, Ma H, et al. . 2021. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. J Exp Med 218 :10. doi:10.1084/jem.20210469
229 Bohrer AC, Castro E, Tocheny CE, Assmann M, Schwarz B, Bohrnsen E, Makiya MA, Legrand F, Hilligan KL, Baker PJ, et al. . 2022. Rapid GPR183-mediated recruitment of eosinophils to the lung after Mycobacterium tuberculosis infection. Cell Rep 40 :111144. doi:10.1016/j.celrep.2022.111144 35905725
230 Rodrigo-Muñoz JM, Gil-Martínez M, Sastre B, Del Pozo V. 2021. Emerging evidence for pleiotropism of eosinophils. Int J Mol Sci 22 :7075. doi:10.3390/ijms22137075 34209213
231 LeMessurier KS, Rooney R, Ghoneim HE, Liu B, Li K, Smallwood HS, Samarasinghe AE. 2020. Influenza A virus directly modulates mouse eosinophil responses. J Leukoc Biol 108 :151–168. doi:10.1002/JLB.4MA0320-343R 32386457
232 Silveira JS, Antunes GL, Gassen RB, Breda RV, Stein RT, Pitrez PM, da Cunha AA. 2019. Respiratory syncytial virus increases eosinophil extracellular traps in a murine model of asthma. Asia Pac Allergy 9 :e32. doi:10.5415/apallergy.2019.9.e32 31720243
233 Godwin MS, Reeder KM, Garth JM, Blackburn JP, Jones M, Yu Z, Matalon S, Hastie AT, Meyers DA, Steele C. 2019. IL-1RA regulates immunopathogenesis during fungal-associated allergic airway inflammation. JCI Insight 4 :e129055. doi:10.1172/jci.insight.129055 31550242
234 Eddens T, Elsegeiny W, Nelson MP, Horne W, Campfield BT, Steele C, Kolls JK. 2015. Eosinophils contribute to early clearance of pneumocystis murina infection. J Immunol 195 :185–193. doi:10.4049/jimmunol.1403162 25994969
235 Lilly LM, Scopel M, Nelson MP, Burg AR, Dunaway CW, Steele C. 2014. Eosinophil deficiency compromises lung defense against Aspergillus fumigatus. Infect Immun 82 :1315–1325. doi:10.1128/IAI.01172-13 24379296
